FDA Inspection 1149278 — King Bio Inc.

King Bio Inc. — FEI 1053442

The FDA completed an inspection of King Bio Inc. on Aug 12, 2021 in Asheville, NC. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 7 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI)
End Date
Aug 12, 2021
Fiscal Year
2021
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Asheville, NC (United States)

Citations

IDCFRDescription
111221 CFR 211.25(a)Training--operations, GMPs, written procedures
117721 CFR 211.63Equipment Design, Size and Location
144821 CFR 211.111Establishment of time limitations
200321 CFR 211.184(c)Individual inventory record
356721 CFR 211.84(d)(2)Component identification test
358521 CFR 211.110(a)Control procedures to monitor and validate performance
440221 CFR 211.192Written record of investigation incomplete

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.